{"componentChunkName":"component---src-templates-tag-template-js","path":"/author/gan-sk","result":{"data":{"site":{"siteMetadata":{"title":"Bioinformatics Institute Publications","subtitle":"Repository of all published Science Articles by our Researchers, their Group Members and Collaborators."}},"allMarkdownRemark":{"edges":[{"node":{"fields":{"slug":"/posts/2020-01-07-reviewing-hiv-1-gag-mutations-in-protease-inhibitors-resistance-insights-for-possible-novel-gag-inhibitor-designs/"},"frontmatter":{"title":"Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs","date":"2019-09-06T06:39:51.257Z","categories":["Antibody and Product Development","Translational Research Division"],"description":"HIV treatment strategies against viral enzymes are continuously hampered by viral drug resistance. Recent findings show that viral substrate Gag contributes to HIV-1 Protease Inhibitor (PI) resistance, leading to demands for new strategies in HIV treatment where Gag is recognized as a drug target. "}}},{"node":{"fields":{"slug":"/posts/2020-01-03-reviewing-hiv-1-gag-mutations-in-protease-inhibitors-resistance-insights-for-possible-novel-gag-inhibitor-designs-reviewing-hiv-1-gag-mutations-in-protease-inhibitors-resistance-insights-for-possible-novel-gag-inhibitor-designs/"},"frontmatter":{"title":"Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs ","date":"2019-09-06T05:59:40.794Z","categories":["Antibody and Product Development","Translational Research Division"],"description":"HIV treatment strategies against viral enzymes are continuously hampered by viral drug resistance. Recent findings show that viral substrate Gag contributes to HIV-1 Protease Inhibitor (PI) resistance, leading to demands for new strategies in HIV treatment where Gag is recognized as a drug target."}}},{"node":{"fields":{"slug":"/posts/2020-02-27-role-of-the-ige-variable-heavy-chain-in-fcεria-and-superantigen-binding-in-allergy-and-immunotherapy/"},"frontmatter":{"title":"Role of the IgE variable heavy chain in FcεRIa and superantigen binding in allergy and immunotherapy","date":"2019-04-14T02:59:17.744Z","categories":["Antibody and Product Development","Translational Research Division"],"description":"Background\nVariable heavy chain (VH) family frameworks (FWRs) have been reported to affect antibody receptor and superantigen binding; however, such effects in IgE remain largely unknown. Given that VH family biases have been previously reported in IgE of certain allergies, there is a need to investigate this phenomenon for biotechnological and therapeutic purposes."}}}]}},"pageContext":{"tag":"Gan SK","currentPage":0,"postsLimit":8,"postsOffset":0,"prevPagePath":"/author/gan-sk","nextPagePath":"/author/gan-sk/page/1","hasPrevPage":false,"hasNextPage":false}}}